### 1 Poor evidence for an effect of tecovirimat in shortening recovery time in hospitalized mpox

### 2 cases from real-world data

- 3
- 4 Mazzotta V<sup>\*<sup>\$1-2</sup></sup>, Cozzi-Lepri A<sup>\$3</sup>, Lanini S<sup>1</sup>, Mondi A<sup>1</sup>, Carletti F<sup>4</sup>, Tavelli A<sup>5</sup>, Gagliardini R<sup>1</sup>,
- 5 Vita S<sup>1</sup>, Pinnetti C<sup>1</sup>, Aguglia C<sup>1</sup>, Faccendini P<sup>6</sup>, Colavita F<sup>4</sup>, Faraglia F<sup>1</sup>, Beccacece A<sup>1</sup>, Paulicelli
- $J^1$ , Girardi E<sup>7</sup>, Nicastri E<sup>1</sup>, Vaia F<sup>8</sup>, Maggi F<sup>4</sup>, Antinori A<sup>1</sup>.
- 7
- 8 <sup>1</sup>Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases
- 9 Lazzaro Spallanzani IRCCS, Rome, Italy;
- 10 <sup>2</sup>PhD course in Microbiology, Immunology, Infectious Diseases, and Transplants (MIMIT),
- 11 University of Rome Tor Vergata, Rome, Italy;
- <sup>12</sup> <sup>3</sup>Centre for Clinical Research, Epidemiology, Modelling, and Evaluation (CREME), Institute for
- 13 Global Health, UCL, London, UK;
- <sup>4</sup>Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS,
- 15 Rome, Italy;
- <sup>16</sup> <sup>5</sup>Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo,
- 17 University of Milan, Italy;
- <sup>6</sup>Pharmacy Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome,
- 19 Italy;
- <sup>20</sup> <sup>7</sup>Scientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome,
- 21 Italy;
- <sup>8</sup>General Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome,
- 23 Italy.
- 24
- 25 <sup>\$</sup>These authors equally contributed
- 26
- 27 \*Corresponding Author:
- 28 Valentina Mazzotta, MD
- 29 **ORCID:** 0000-0002-0240-7504
- 30 Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases
- 31 Lazzaro Spallanzani IRCCS,
- 32 Via Portuense 292, 00149 Rome, Italy
- 33 Phone: +39 06 55170546
- 34 Fax: +39 06 55170477

- 35 e-mail: valentina.mazzotta@inmi.it
- 36 Abstract

37 **Objectives** To assess the effectiveness of tecovirimat (TPOXX) for treating mpox in terms of

38 difference in healing time and extent of viral clearance.

39 **Design** Emulation of a target trial based on observational data.

40 **Setting** Italy

41 **Participants** Forty-one men hospitalized for mpox as of September 29<sup>th</sup>, 2022.

42 **Main outcome measures** Main outcome was the time to clinical recovery. Secondary outcome was

43 the variation in viral load in the upper respiratory tract (URT) after treatment.

44 **Results** The median time from symptoms onset to hospital admission and to initiation of TPOXX

45 was 4 days (IQR 2-6) and 10 days (IQR 8-11), respectively. Fifteen patients completed a course of

therapy. No deaths were observed; the overall median healing time was 21 days (IQR 17-26). We

47 found no evidence for a significant improvement in recovery time in treated vs. untreated patients,

48 with an estimated mean of 14.7 days for both groups. A subset of 13 patients had URT samples at

49 T1 (median of 5 days (IQR 3-7) from symptoms onset) and T2 (median 7 days (IQR 7-9) from T1).

50 Overall, mean viral load was 4.65 (0.30) vs. 4.91 (0.35) (log2 scale of cycle threshold) at T1 and

51 T2, respectively. In the unadjusted analysis, variation over T1-T2 was lower in the treated 0.13 log2

52 (SD=0.53) vs. untreated 0.37 (0.50), although not statistically significant (unpaired t-test p=0.41).

53 After controlling for confounding, there was no evidence for a difference in the potential changes

54 over T1-T2 by treatment arm, and our estimate of the average treatment effect (ATE) was consistent

55 with no difference by treatment group, although with large 95% CI around these estimates.

56 **Conclusions** Our analysis seems to exclude a clinically important effect of TPOXX in hospitalized 57 mpox patients when compared to no treatment. These data are one of the valuable currently 58 available sources of evidence to guide treatment decisions in patients hospitalized with TPOXX.

59 Pending more robust data from randomized comparisons, the use of TPOXX should be restricted to

60 the clinical trials setting.

Trial registration – "MpoxCohort" observational study protocol: approval number 40z, Register of
 Non-Covid Trials 2022.

63

64

#### 65 Introduction

66 On July 23, 2022, the World Health Organization (WHO) declared mpox to be a Public Health 67 Emergency of International Concern (PHEIC) <sup>[1]</sup>. Among the 85,159 mpox confirmed cases 68 registered worldwide as of January 29<sup>th</sup>, 2023, only 88 deaths occurred<sup>[2]</sup>, and usually, the disease 69 improved without any antiviral treatment. However, complications leading to hospitalization may 70 occur, and the illness may last for several weeks, during which patients are forced into isolation.

The Centers for Disease Control and Prevention (CDC) suggested to consider mpox treatment in people with severe disease or involvement of anatomic areas, which might result in serious sequelae, or in immunocompromised people or at high risk for severe disease<sup>[3]</sup>. Moreover, the recommended timing for the start of therapy is early after onset.

75 However, there are currently no proven therapeutics to shorten healing times in mpox. Tecovirimat (TPOXX) was authorized in USA<sup>[4]</sup> and EU<sup>[5]</sup> for use against mpox based on promising results from 76 initial studies in animals<sup>[6]</sup> and evidence of safety in healthy human volunteers<sup>[7]</sup>; TPOXX is also 77 the first choice treatment for mpox suggested by CDC<sup>[3]</sup>. In recent series, oral TPOXX was reported 78 as safe and well tolerated<sup>[8-13]</sup>, no worsening was observed in treated patients, and subjective 79 80 improvement was reported after a median time of 3 days after treatment. However, the lack of a 81 control group made it difficult to assess treatment effectiveness, and the limited supply did not 82 allow the early use of TPOXX. Furthermore, randomized controlled trials (RTCs) are still ongoing<sup>[14-16]</sup>, and there is an urgent need for robust evidence in order to guide clinical decision-83 making<sup>[17]</sup>. Nevertheless, the rapidly decreasing number of mpox cases worldwide will probably not 84 85 allow RCTs to be concluded soon.

86 Our study aimed to assess the difference in healing time and extent of viral clearance between 87 patients treated and untreated with tecovirimat using observational data to emulate a hypothetical 88 target trial.

89

#### 90 Methods

#### 91 Study Population

92 We included all adult patients with laboratory-confirmed mpox admitted at the Lazzaro Spallanzani

National Institute for Infectious Diseases (INMI; Rome, Italy) from May 19<sup>th</sup> to September 29<sup>th</sup> and

94 hospitalized for mpox.

95 Demographic, epidemiological, and clinical characteristics were collected at the time of diagnosis,

and diagnostic testing for the mpox virus (MPXV) was performed.

97 The patients treated with TPOXX received a course of 600 mg twice daily for 14 days: the decision

98 regarding treatments was based on international medical consensus and the availability of drugs.

99 Participants were followed-up for at least 30 days from symptoms onset until complete clinical100 recovery or last clinical follow-up.

Data on MPXV viral load in samples collected during the hospitalization from upper respiratory tract (URT), including oropharyngeal swabs and saliva, were recorded. Viral DNA was extracted by the automatic extractor QIAsymphony (Qiagen, Hilden, Germany), and amplified using the realtime PCR method targeting the tumor necrosis factor receptor gene, G2R. MPXV DNA concentration was measured using cycle threshold (Ct) values of the MPXV-specific PCR. All patients provided written informed consent to participate in the study. The study was approved

107 by the Ethical Committee of the Lazzaro Spallanzani Institute (MpoxCohort protocol: "*Studio di* 108 *coorte osservazionale monocentrica su soggetti che afferiscono per sospetto clinico o* 109 *epidemiologico di malattia del vaiolo delle scimmie (Monkeypox)*"; approval number 40z, Register

110 of Non-Covid Trials 2022).

111

#### 112 <u>Statistical analysis</u>

Because the time of symptom onset did not coincide with the date of treatment initiation, to assess the effectiveness of TPOXX, in our target population, we used a counterfactual framework accounting for immortal time bias.

The primary endpoint for the comparison between treated and untreated patients was the time from the date of symptom onset to achieving complete clinical recovery by day 21, defined as the healing of skin and mucosal lesions. Our secondary endpoint was the variation in Ct values in URT from a median of 6 days from the date of symptom onset (T1) to a median of 5 days after T1 (T2).

120 For the primary endpoint analysis, we aimed to emulate a parallel trial design. The treatment 121 strategies were defined as to start or not to start TPOXX within 10 days from symptoms onset; this 122 interval has been consequently chosen as the grace period in the analysis. The per-protocol effect of 123 TPOXX initiation within 10 days of clinical onset on the primary outcome was quantified by the 124 differences between strategies in (i) not achieving clinical recovery by day 21 (failure) and (ii) restricted mean survival times (survival time difference over a 21-days window)<sup>[18]</sup>. We assumed 125 126 that at hospital admission all participants were equally likely to be offered treatment with TPOXX. 127 We created two clones of each participant, with one clone allocated to each strategy, hence 128 doubling the size of our dataset. The study arms in this newly created pseudo-population were, 129 therefore, identical with respect to demographics and clinical characteristics at the time of entering 130 the hospital, thus minimising confounding bias at baseline. In each arm, participants' follow-up 131 times have been censored when their treatment was no longer compatible with the treatment 132 strategy for the arm (e.g. when there was a deviation from the planned protocol). In our analysis,

133 this occurred for: (i) participants in the no TPOXX arm (control) who received TPOXX within 10 134 days from symptoms onset and whose follow-up was censored at their time of starting TPOXX and 135 (ii) participants in the treated arm who did not receive TPOXX within 10 days from symptoms 136 onset and whose follow-up was censored at 10 days (including participants who started TPOXX 137 after 10 days). For each participant, clinical recovery by day 21 (if achieved at all) was attributed to 138 the arm in which the participant was still uncensored at the time of the event (i.e., the arm the 139 participant is compliant with). Because there are common causes of the probability of treatment 140 initiation and that of clinical recovery, the artificial censoring introduced by cloning is usually 141 informative. For the comparison of interest, we identified the following potential confounders: age, 142 HIV status, and disease severity, defined as the presence of more than 20 skin lesions and/or 143 involvement of anatomic areas which might result in serious sequelae (e.g., proctitis, 144 pharyngotonsillitis, or ocular involvement). We use inverse probability of censoring weights to 145 control for the cloning-induced informative censoring bias. The 95% Cis were calculated using 100 146 bootstrap replicates.

147 In the analysis of the secondary endpoint (Ct variation over time), in order to control for immortal time bias, we used a 'matching on time' type of analysis<sup>[19]</sup>. In this approach, participants who 148 149 initiated TPOXX after hospitalisation were matched to those who did not receive TPOXX and were 150 followed-up for the same amount of time from the date of symptom onset. For example, if a 151 participant started TPOXX 5 days after the date of symptom onset (T1) and had a Ct value 152 measured at T1, the patient was matched to another participant who had not received TPOXX by 5 153 days who also had a Ct value measured at T1, and both were followed-up from T1 onwards until a 154 second time point (T2) in which a second Ct value was available. We then compared the Ct 155 variation over T1-T2 (in the log2 scale), again by emulating a parallel trial in which TPOXX was 156 the intervention of interest. The average causal effect of TPOXX was estimated using marginal 157 models in which, to control for the effects of age and disease severity, we modelled both the 158 exposure (through inverse probability weighting) and the outcome (via regression) or both (doubly 159 robust). This secondary endpoint analysis was restricted to participants with a Ct value from 160 samples collected from URT available at T1 and T2, and with a T1 value <35. We also conducted a 161 sensitivity analysis controlling for age and HIV status (numerical problems prevented the 162 adjustment for all 3 identified confounders at the same time in this analysis).

163

#### 164 **Results**

Forty-one hospitalized subjects with mpox were included as of September 29<sup>th</sup>, 2022. Among the 41 patients enrolled, 15 completed a course of TPOXX therapy. In Table 1 main characteristics of

167 patients according to TPOXX exposure were reported. All participants were male, and 95% were 168 self-reported as men who had sex with men. Median age was 35 years (IQR 32-39), and 78% were 169 Caucasian. Only 3 (7.3%) received smallpox vaccine during childhood. Fifteen (36.6%) patients 170 were living with HIV and 17% were HIV negative and received pre-exposure prophylaxis with antiretrovirals; median CD4 cells count in HIV infected was 684 cell/mm<sup>3</sup> (IQR 471, 884), with no 171 evidence for a difference between TPOXX treated and untreated individuals (Table 1). Overall, 172 173 95% of patients had systemic symptoms, and 25 (61%) were classified as having severe disease; 18 174 (43.9%) had more than 10 mpox cutaneous lesions and main organ disease localizations were 175 proctitis (26.8%), and pharyngotonsillitis (22%). In the original cohort, before cloning took place, 176 the median time from symptoms onset to hospital admission was 4 days (IQR 2-6). The main 177 reasons for hospitalization and treatment were mucosal inflammation and/or superinfection of the 178 lesions and/or management of severe pain due to the lesions. The median time from symptoms 179 onset to initiation of TPOXX was 10 days (IQR 8-11). No deaths were observed, and the overall 180 median time for clinical recovery was 21 days (IQR 17-26).

Our emulation of a parallel trial design analysis showed that, although the risk of 21-day failure was 4.1% lower in participants who were treated with TPOXX vs. those who remained untreated, the 95% CI was large and did not exclude benefit or harm of treatment. Similarly, no significant improvement in recovery time was observed in treated patients, with a mean of 14.7 days estimated for both the treated and untreated groups (Table 2).

186 A total of 122 URT samples were collected from 15 treated and 19 untreated patients. Among these, 187 a subset of 13 patients (6 treated and 7 untreated) who had a T1 value <35 and had a second sample 188 at a following time T2, were included in the analysis. Main characteristics of these 13 patients are 189 shown in Supplementary Table 1 and were similar to those of the full cohort. T1 was a median 190 (IQR) of 5 days (3-7) from the date of onset of symptoms, and T2 was 7 days (7-9) from T1. As a 191 consequence of the matching, the timing of T1 and T2 was similar in treated and untreated. 192 Overall, mean Ct values were 25.6 (SD 5.05) and 30.7 (SD 6.6) in the raw scale and 4.65 (0.30) vs. 193 4.91 (0.35) in the log2 scale at T1 and T2, respectively. The variation over T1-T2 is expressed as 194 the value at T2 minus the value at T1 so positive changes indicate that the participants had a 195 decrease in viral load at T2 (increase in Ct value). In the unadjusted analysis, such increase was 196 lower in the treated 0.13 log2 (0.53) vs. untreated 0.37 (0.50) suggesting poor virological potency of 197 treatment, although not statistically significant (unpaired t-test p=0.41). Results were confirmed by 198 the trial emulation analysis which, after controlling for confounding, showed no evidence for a 199 difference in the potential changes over T1-T2 by treatment arm and our estimate of the average

treatment effect (ATE) was consistent with no difference by treatment group, again with large 95%CI around these estimates.

- 202
- 203

#### 204 **Discussion**

205 Our trial emulation analysis failed to show a clinical benefit of TPOXX on recovery time or an 206 effect on viral replication in participants who were hospitalized with mpox. The emulation analysis 207 was based on a couple of firm points regarding the choice of the primary outcome, and target 208 population used. At this point in time, given the low case fatality rate of mpox and the required 209 isolation during the presence of active skin lesions, time to recovery could be considered as the primary clinical outcome to be used also in randomized trials<sup>[16]</sup>. our target trial population was 210 211 restricted to hospitalized patients because the use of TPOXX is currently only suggested for persons with severe mpox<sup>[3]</sup>. In absence of the results from randomized studies our results represent a 212 213 valuable source of evidence for the effectiveness of TPOXX in this setting.

Similarly to other disease models<sup>[20-22]</sup>, characterizing the early stage of infection as the viral response phase, also for mpox, a timely initiation of TPOXX is believed to be critical for the effectiveness of the treatment. This is because TPOXX is an antiviral and it is reasonable to assume that a prompt reduction in viral replication would lead to quicker clinical recovery.

Our previous, uncontrolled, descriptive data on treated mpox patients showed a progressive decline in MPXV viral load in the course of antiviral treatment<sup>[10]</sup>; nevertheless, in other cohorts<sup>[23-24]</sup> of untreated patients, viral shedding also occurred mainly during the first two weeks of the disease after which it naturally declined. In our present analysis, there was no evidence for a difference in viral load reduction after an average of 12 days from the date of symptoms onset when comparing treated versus untreated mpox patients after controlling for potential immortal and confounding bias.

225 Our analysis has a number of limitations. First of all, treatment was not randomly allocated and was 226 initiated a number of days after the date of clinical onset/hospitalization. The delay in treatment 227 initiation was due, in first instance, to the fact that hospitalization typically occurred several days 228 after clinical onset. In addition, once the patient was in the hospital, treatment initiation could have 229 been further delayed by limited drug availability for two main reasons: i) the drug is typically 230 available only for large stocks, and our single-center study has limited sample size; ii) the high cost 231 of the drug. Indeed, in our cohort, the average delay in starting treatment was 10 days after the date 232 of clinical onset. This is consistent with the data of other similar reports showing an average delay of 7-21 days for treatment initiation after hospitalization<sup>[8-10-13]</sup>. This delay in treatment initiation 233

appeared to have led to an artificial beneficial effect of TPOXX in the original cohort analysis, which indeed showed a larger difference between arms for the main outcomes of risk of failure by day 21 and length of clinical recovery. However, immortal time and confounding bias were minimized by our cloning and weighting approach to analysis, which showed a largely attenuated difference by study arm. In addition, by using a fixed grace period of 10 days for treatment initiation, our analysis cannot address the question of whether greater effectiveness of TPOXX might be achieved by, for example, initiating therapy earlier.

- 241 Second, our study, especially for the analysis of the virological endpoint, has a very limited sample 242 size and, consequently had low statistical power to detect a difference between arms. Although 243 there seems to be no evidence for a difference by arm from looking at our point estimates, there was 244 a large uncertainty around the estimates, and both benefit and harm could not be excluded with 95% 245 confidence. Third, URT sample collection and storage varied by participants and over time, and 246 therefore the analysis of the virological endpoint could be conducted only on a small subset of the 247 study population. However, the selection appeared to be fairly random, and the characteristics of the 248 included population were similar to those of the whole cohort. Last but not least, as usual when 249 using observational data, we cannot rule out unmeasured confounding bias.
- 250 In conclusion, our analysis seems to be able to exclude a clinically important effect of TPOXX in 251 hospitalized mpox patients when compared to no treatment. Despite all the mentioned limitations, 252 our careful analysis of observational data represents one of the valuable current sources of evidence 253 to guide clinical decisions. In light of the fact that most patients seem to recover after a short 254 clinical course of the disease, although a proper cost-effectiveness analysis needs to be conducted, 255 our results, together with the high cost of the drug, appear to suggest a low cost-effectiveness of 256 TPOXX for the treatment of mpox. For these reasons, while awaiting more solid data coming from 257 randomized comparisons, we believe that the use of TPOXX should be restricted to patients 258 enrolled in clinical trials.

#### 259 Contributors

- 260 VM, ACL, and AA contributed to the study concept and design, analysis, and interpretation of data.
- 261 SL contributed to the critical revision of the manuscript for important intellectual content.
- AT, CA, JP, and AB acquired the data. VM and ACL drafted the manuscript. ACL did the statistical
- analysis. AM, CP, RG, SV, and FF reviewed the manuscript. FC, FCo, and FM were responsible for
- the virological data. VM and AA are guarantors. All authors reviewed the manuscript.
- 265 The corresponding author attests that all listed authors meet authorship criteria and that no others
- 266 meeting the criteria have been omitted.
- 267

#### 268 Ethical statement

- 269 Data were recorded as part of routine activities and from database of the observational study
- 270 approved by the Ethical Committee of the Lazzaro Spallanzani Institute (MpoxCohort protocol:
- 271 "Studio di coorte osservazionale monocentrica su soggetti che afferiscono per sospetto clinico o
- 272 epidemiologico di malattia del vaiolo delle scimmie (Monkeypox)"; approval number 40z, Register
- of Non-Covid Trials 2022). Data have been analysed anonymously.

#### 274 **Funding statement**

Funds from the Italian Ministry of Health to INMI Spallanzani, Ricerca Corrente Linea 1 and 2.

#### 276 **Conflicts of interests**

- 277 All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-
- 278 interest/ and declare no conflict of interest for the present study.
- 279• The corresponding author (CC) affirms that the manuscript is an honest, accurate, and transparent
- account of the study being reported, no important aspects of the study have been omitted, and any
- 281 discrepancies from the study as planned have been explained.

#### 282 Acknowledgments

283 We acknowledge all the participants, nursing staff and the INMI Mpox Study Group: Isabella 284 Abbate, Alessandro Agresta, Camilla Aguglia, Alessandra Amendola, Andrea Antinori, Francesco 285 Baldini, Tommaso Ascoli Bartoli, Alessia Beccacece, Rita Bellagamba, Giulia Berno, Aurora 286 Bettini, Nazario Bevilacqua, Licia Bordi, Marta Camici, Priscilla Caputi, Fabrizio Carletti, Rita 287 Casetti, Angela Corpolongo, Stefania Cicalini, Eleonora Cimini, Francesca Colavita, Alessandra 288 D'Abramo, Angela D'Urso, Gabriella De Carli, Patrizia De Marco, Federico De Zottis, Silvia Di 289 Bari, Lavinia Fabeni, Francesca Faraglia, Valeria Ferraioli, Carla Fontana, Federica Forbici, 290 Concetta Maria Fusco, Marisa Fusto, Roberta Gagliardini, Anna Rosa Garbuglia, Saba

291 Gebremeskel Teklé, Maria Letizia Giancola, Giuseppina Giannico, Simona Gili, Emanuela 292 Giombini, Enrico Girardi, Giulia Gramigna, Germana Grassi, Elisabetta Grilli, Susanna Grisetti, 293 Cesare Ernesto Maria Gruber, Eleonora Lalle, Simone Lanini, Daniele Lapa, Gaetano Maffongelli, 294 Fabrizio Maggi, Alessandra Marani, Andrea Mariano, Ilaria Mastrorosa, Giulia Matusali, Silvia 295 Meschi, Valentina Mazzotta, Sabrina Minicucci, Claudia Minosse, Klizia Mizzoni, Martina 296 Moccione, Annalisa Mondi, Vanessa Mondillo, Giorgia Natalini, Nicoletta Orchi, Sandrine Ottou, 297 Jessica Paulicelli, Elisabetta Petrivelli, Maria Maddalena Plazzi, Carmela Pinnetti, Silvia Pittalis, 298 Gianluca Prota, Vincenzo Puro, Silvia Rosati, Alberto Rossi, Gabriella Rozera, Marika Rubino, 299 Martina Rueca, Laura Scorzolini, Eliana Specchiarello, Maria Virginia Tomassi, Massimo 300 Tempestilli, Francesco Vaia, Francesco Vairo, Beatrice Valli, Alessandra Vergori, Serena Vita.

301

#### 302 **References**

303 [1] WHO. Second meeting of the International Health Regulations (2005) (IHR) Emergency

304 Committee regarding the multi-country outbreak of monkeypox. July 23,

305 2022. https://www.who.int/news/item/23-07-2022-second-meeting-of-the-international-health-

306 regulations-(2005)-(ihr)-emergency-committee-regarding-the-multi-country-outbreak-of-

307 monkeypox

308 [2] Centers and Disease Control and Prevention: 2022 Monkeypox Outbreak Global Map. Data as

309 of 29 Jan 2023 5:30 PM EDT. https://www.cdc.gov/poxvirus/monkeypox/response/2022/world-

- 310 map.html. Accessed January 31, 2023.
- 311 [3] Centers and Disease Control and Prevention: Interim Clinical Guidance for the Treatment of
- 312Monkeypox.UpdatedOctober31,2022.
- 313 https://www.cdc.gov/poxvirus/monkeypox/clinicians/treatment.html. Accessed January 31, 2023.

[4] Highlights of Prescribing Information (TPOXX). Food and Drug Administration (Updated May
 2022)Accessed January 31, 2023.

316 <u>https://www.accessdata.fda.gov/drugsatfda\_docs/label/2022/214518s000lbl.pdf</u>

317 [5] European Medicines Agency: Tecovirimat EPAR- Medicine overview. EMA/44982/2022.

318 January 28, 2022. https://www.ema.europa.eu/en/documents/overview/tecovirimat-siga-epar-

- 319 medicine-overview\_en.pdf
- 320 [6] Yang G, Pevear DC, Davies MH, et al. An orally bioavailable antipoxvirus compound (ST-246)
- 321 inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J

322 Virol. 2005;79(20):13139-13149. doi:10.1128/JVI.79.20.13139-13149.2005

- 323 [7] Grosenbach DW, Honeychurch K, Rose EA, et al. Oral Tecovirimat for the Treatment of
- 324 Smallpox. N Engl J Med. 2018;379(1):44-53. doi:10.1056/NEJMoa1705688

- 325 [8] Desai AN, Thompson GR 3rd, Neumeister SM, Arutyunova AM, Trigg K, Cohen SH.
- 326 Compassionate Use of Tecovirimat for the Treatment of Monkeypox Infection. JAMA.
- 327 2022;328(13):1348-1350. doi:10.1001/jama.2022.15336
- 328 [9] Mondi A, Gagliardini R, Mazzotta V, et al. Clinical experience with use of oral Tecovirimat or
- 329 Intravenous Cidofovir for the treatment of Monkeypox in an Italian reference hospital. J Infect.
- 330 2023;86(1):66-117. doi:10.1016/j.jinf.2022.11.001
- 331 [10] Mbrenga F, Nakouné E, Malaka C, et al. Tecovirimat for Monkeypox in Central African
- 332 Republic under Expanded Access. N Engl J Med. 2022;387(24):2294-2295.
  333 doi:10.1056/NEJMc2210015
- 334 [11] Adler H, Gould S, Hine P, et al. Clinical features and management of human monkeypox : a
- retrospective observational study in the UK. Lancet Infect Dis 2022;3099:1–10.
- 336 [12] Matias WR, Koshy JM, Nagami EH, et al. Tecovirimat for the Treatment of Human
- Monkeypox: An Initial Series From Massachusetts, United States. Open forum Infect Dis2022;9:ofac377.
- 339 [13] O'Laughlin K, Tobolowsky FA, Elmor R, et al. Clinical Use of Tecovirimat (Tpoxx) for
- 340 Treatment of Monkeypox Under an Investigational New Drug Protocol United States. MMWR
- 341 Morb Mortal Wkly Rep May-August 2022. ePub: 9 Septem- ber 2022. DOI: http://dx.doi.
- 342 [14] Tecovirimat for Treatment of Monkeypox Virus. ClinicalTrials.gov Identifier: NCT05559099
- 343 [15] Study of Tecovirimat for Human Monkeypox Virus (STOMP). ClinicalTrials.gov Identifier:
   344 NCT05534984
- 345 [16] Tecovirimat in Non-hospitalized Patients With Monkeypox (PLATINUM-CAN).
  346 ClinicalTrials.gov Identifier: NCT05534165
- [17] Lindholm DA, Kalil AC. Déjà vu all over again? Monkeypox and the urgent need for
  randomised controlled trials. Lancet Infect Dis. 2023;23(2):e56-e58. doi:10.1016/S14733099(22)00722-8
- 350 [18] Hernán MA, Sauer BC, Hernández-Díaz S, Platt R, Shrier I. Specifying a target trial prevents
- 351 immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol.
- 352 2016;79:70-75. doi:10.1016/j.jclinepi.2016.04.014
- [19] Dekkers OM, Groenwold RHH. When observational studies can give wrong answers: the
   potential of immortal time bias. Eur J Endocrinol. 2021;184(1):E1-E4. doi:10.1530/EJE-20-1124
- 355 [20] Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk,
- 356 Nonhospitalized Adults with Covid-19. N Engl J Med. 2022;386(15):1397-1408.
- 357 doi:10.1056/NEJMoa2118542

- 358 [21] Wood M. J., Kay R., Dworkin R. H., et al. Oral acyclovir therapy accelerates pain resolution in
- patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin. Infect.Dis. 1996;22:341–347.
- [22] Wallace M. R., Bowler W. A., Murray N. B. Treatment of adult varicella with oral
   acyclovir. Ann. Intern. Med. 1992;117:358–363
- 363 [23] Peiro-Mestres A, Fuertes I, Camprubi-Ferrer D, et al. Frequent detection of mon- keypox virus
- 364 DNA in saliva, semen, and other clinical samples from 12 pa- tients, Barcelona, Spain, May to June
- 365 2022. *Eurosurveillance* 2022;27. Available at <u>http://dx.doi.org/10.2807/1560-</u>
  366 7917.ES.2022.27.28.2200503.
- 367 [24] Suñer C, Ubals M, Tarín-Vicente EJ, et al. Viral dynamics in patients with monkeypox
- 368 infection: a prospective cohort study in Spain [published online ahead of print, 2022 Dec
- 369 12]. Lancet Infect Dis. 2022;S1473-3099(22)00794-0. doi:10.1016/S1473-3099(22)00794-0.

# Table 1. Main characteristics of hospitalized patients with monkeypox according to the administration of tecovirimat.

Characteristics	Treated with Tecovirimat	Untreated	p-value <sup>*</sup>	Total
	N=19	N= 22		N= 41
Age, years, median (IQR)	38 (34, 46)	33 (29, 39)	0.017	35 (31, 39)
Smallpox vaccination, n (%)	1 (5.3%)	2 (9.1%)	0.643	3 (7.3%)
Caucasian, n (%)	15 (78.9%)	17 (77.3%)	0.898	32 (78.0%)
MSM <sup>a</sup> , <i>n</i> (%)	18 (94.7%)	21 (95.5%)	0.916	39 (95.1%)
Use of Chemsex, n (%)	0 (0.0%)	2 (16.7%)	0.166	2 (8.7%)
HIV+, <i>n</i> (%)	7 (36.8%)	8 (36.4%)	0.975	15 (36.6%)
CD4 count <sup>b</sup> , days, median (IQR)	714 (471, 1323)	661 (390, 823)	0.487	684 (471, 884)
Use of $PrEP^c$ , $n$ (%)	3 (15.8%)	4 (18.2%)	0.841	7 (17.1%)
Route of transmission, $n$ (%)			0.373	
Recent reported sexual intercourses	18 (94.7%)	21 (95.5%)		39 (95.1%)
Household	0 (0.0%)	1 (4.5%)		1 (2.4%)
Systemic symptoms, n (%)	19 (100.0%)	20 (90.9%)	0.183	39 (95.1%)
Number of skin lesions, $n$ (%)			0.740	
0-4	6 (31.6%)	9 (40.9%)		15 (36.6%)
5-10	4 (21.1%)	4 (18.2%)		8 (19.5%)
11-20	6 (31.6%)	4 (18.2%)		10 (24.4%)
21+	3 (15.8%)	5 (22.7%)		8 (19.5%)
Pharyngotonsillitis, n (%)	6 (31.6%)	3 (13.6%)	0.172	9 (22.0%)
Proctitis, <i>n</i> (%)	6 (31.6%)	5 (22.7%)	0.529	11 (26.8%)
Ocular Lesions, n (%)	2 (10.5%)	1 (4.5%)	0.469	3 (7.3%)
Severity of disease <sup>d</sup> , $n$ (%)	12 (63.2%)	13 (59.1%)	0.793	25 (61.0%)
Concurrent STIs <sup>e</sup> , n (%)	11 (73.3%)	9 (69.2%)	0.814	20 (71.4%)
Gonorrhoea	1 (5.3%)	0 (0.0%)		1 (2.4%)
Syphilis	4 (21.1%)	4 (18.2%)		8 (19.5%)
Other	6 (31.6%)	5 (22.7%)		11 (26.8%)
Time from onset to hospital admission,	5 (2, 6)	4 (2, 6)	0.462	4 (2, 6)
days, median (IQR)				
Time from onset to treatment start,	10 (8, 11)			10 (8, 11)
days, median (IQR)				
Clinical recovery, days, median (IQR)	23 (18, 29)	20 (16, 23)	0.053	21 (17, 26)

<sup>a</sup> Men who have sex with men,

<sup>b</sup> available only in HIV+ participants,

<sup>c</sup> Pre-exposure prophylaxis for HIV

<sup>d</sup> More than 20 skin lesions and/or presence of ocular lesions and/or pharyngotonsillitis and/or proctitis

<sup>e</sup> Sexually transmitted infections;

\*Chi-square or Mann-Whitney U test as appropriate

## Table 2. Results of emulation of a parallel trial design with the target population of participants admitted to the hospital for Mpox.

It was assumed that treatment initiation was based on the following confounders: age, disease severity, and HIV status. Inverse probability of censoring weights was used to control for the cloning-induced informative censoring bias.

Original cohort	21-day failure (%)	95% (	CI*	Recovery days	95% C	JI*
Tecovirimat arm <sup>\$</sup>	8.3	0.0	33.3	8.4	1.9	9.2
No Tecovirimat arm	22.2	0.0	55.9	11.7	7.6	12.7
Differences <sup>1</sup>	-13.9	-5.2	+21.0	-3.3	-8.8	+0.4
Emulated cohort	21 day failure (%)	95% (	CI*	Recovery days	95% C	ĽI∗
Kaplan-Meier						
Tecovirimat arm	12.5	0.0	50.5	14.7	12.5	14.9
No Tecovirimat arm	15.4	0.0	31.4	14.7	12.4	14.9
Differences <sup>2</sup>	-2.9	-29.2	+33.5	-0.01	-0.11	+0.13
Weighted Kaplan-Meier						
Tecovirimat arm	9.8	0.0	45.4	14.7	12.5	14.9
No Tecovirimat arm	13.9	0.0	29.3	14.7	12.4	14.9
Differences <sup>3</sup>	-4.1	-29.2	+30.8	-0.02	-0.11	+0.12

<sup>\$</sup> Tecovirimat was administered at the dosage of 600 mg twice daily for 14 days

\* The 95% CIs were calculated using 100 bootstrap replicates

1 These differences are prone to both confounding and immortal-time biases

2 These differences are prone to informative censoring

3 These differences account for all types of biases under the assumptions detailed in the methods.

# Table 3. Potential cycle threshold (Ct) changes (log2 scale) over T1-T2 and Average treatment effect (ATE) from fitting a linear regression model.

Potential Ct changes (log2 scale) over T1-T2 <sup>\$</sup> and ATE <sup>&amp;</sup> from fitting a linear regression model								
	Mean	Mean						
	in treated with TPOXX	in untreated	ATE <sup>*</sup> (95% CI)	p-value				
	(95% CI)	(95% CI)						
Treated vs. Untreated								
IPWs	0.25 (-0.02, 0.53)	0.41 (0.08, 0.73)	-0.16 (-0.64, 0.33)	0.529				
Double Robust	0.38 (0.13, 0.64)	0.41 (-0.01, 0.84)	-0.03 (-0.58, 0.53)	0.920				
Regression adjustment	0.38 (0.00, 0.76)	0.37 (0.01, 0.74)	0.01 (-0.56, 0.57)	0.979				

<sup>\$</sup>T1 was a median of 6 days after symptoms onset; T2 a median of 5 days after T1

& Average Treatment Effect

\*weighted for age and HIV status